Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12156
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHolter Chakrabarty, Jennifer Len
dc.contributor.authorRubinger, Morelen
dc.contributor.authorLe-Rademacher, Jenniferen
dc.contributor.authorWang, Hai-Linen
dc.contributor.authorGrigg, Andrew Pen
dc.contributor.authorSelby, George Ben
dc.contributor.authorSzer, Jeffreyen
dc.contributor.authorRowe, Jacob Men
dc.contributor.authorWeisdorf, Daniel Jen
dc.contributor.authorTallman, Martin Sen
dc.date.accessioned2015-05-16T01:48:26Z
dc.date.available2015-05-16T01:48:26Z
dc.date.issued2014-03-30en
dc.identifier.citationBiology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation 2014; 20(7): 1021-5en
dc.identifier.govdoc24691221en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12156en
dc.description.abstractTo identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allogeneic (n = 232) or autologous (n = 62) hematopoietic cell transplantation (HCT) reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with pre-HCT PML/RAR∝ status (49% of allogeneic and 66% of autologous). Patient characteristics and transplantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free survival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of 115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63% (49% to 75%), compared with allogeneic at 50% (44% to 57%) (P = .10). OS was 75% (63% to 85%) versus 54% (48% to 61%) (P = .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis showed significantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.16 to 3.06; P = .011) and age > 40 years (HR, 2.30; 95% CI, 1.44 to 3.67; P = .0005). OS was significantly worse after allogeneic HCT (HR, 2.66; 95% CI, 1.52 to 4.65; P= .0006); age > 40 (HR, 3.29; 95% CI, 1.95 to 5.54; P < .001), and first complete remission < 12 months (HR, 1.56; 95% CI, 1.07 to 2.26; P = .021). Positive pre-HCT PML-RAR∝ status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not influence relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable to increased treatment-related mortality (TRM) in the allogeneic group of 30% compared to 2% in the autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual disease-positive grafts, remains an important subject for further study.en
dc.language.isoenen
dc.subject.otherAPLen
dc.subject.otherAllogeneic transplantationen
dc.subject.otherAutologous transplantationen
dc.subject.otherAdulten
dc.subject.otherDisease-Free Survivalen
dc.subject.otherFemaleen
dc.subject.otherHematopoietic Stem Cell Transplantation.methodsen
dc.subject.otherHumansen
dc.subject.otherLeukemia, Promyelocytic, Acute.therapyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherRemission Inductionen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTransplantation, Autologousen
dc.subject.otherTransplantation, Homologousen
dc.subject.otherYoung Adulten
dc.titleAutologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.en
dc.typeJournal Articleen
dc.identifier.journaltitleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantationen
dc.identifier.affiliationDepartment of Hematology, CancerCare Manitoba, Winnipeg, Canadaen
dc.identifier.affiliationDepartment Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital City Campus, Victoria, Australiaen
dc.identifier.affiliationDepartment Clinical Haematology, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Oklahoma, Oklahoma City, Oklahomaen
dc.identifier.affiliationDivison of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.en
dc.identifier.affiliationCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.en
dc.identifier.affiliationDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma.en
dc.identifier.affiliationDepartment of Hematology and Oncology, Rambam Medical Center, Haifa, Israel.en
dc.identifier.affiliationCenter for International Blood and Marrow Transplant Research, University of Minnesota Medical Center, Minneapolis, Minnesota.en
dc.identifier.affiliationDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.en
dc.identifier.doi10.1016/j.bbmt.2014.03.025en
dc.description.pages1021-5en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24691221en
dc.type.austinJournal Articleen
local.name.researcherGrigg, Andrew P
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.